Lastly, we demonstrate the therapeutic potential of enhancing p300 catalytic activity to treat MDS/AML patients with deficient TET2 function, and potentially individuals with Tet2-mutant clonal hematopoiesis. The gene discussed is EP300; the disease is myelodysplastic syndrome.